The cost-effectiveness of bevacizumab, ranibizumab and aflibercept for the treatment of age-related macular degeneration—A cost-effectiveness analysis from a societal perspective

BACKGROUND: The discussion on the use of bevacizumab is still ongoing and often doctors are deterred from using bevacizumab due to legal or political issues. Bevacizumab is an effective, safe and inexpensive treatment option for neovascular age-related macular degeneration (AMD), albeit unregistered...

Descripción completa

Detalles Bibliográficos
Autores principales: van Asten, Freekje, Michels, Charlotte T. J., Hoyng, Carel B., van der Wilt, Gert Jan, Klevering, B. Jeroen, Rovers, Maroeska M., Grutters, Janneke P. C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5957378/
https://www.ncbi.nlm.nih.gov/pubmed/29772018
http://dx.doi.org/10.1371/journal.pone.0197670

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5957378/
https://www.ncbi.nlm.nih.gov/pubmed/29772018
http://dx.doi.org/10.1371/journal.pone.0197670

Ejemplares similares